Cabaletta Bio Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress

Reuters

06-11

<a href="https://laohu8.com/S/CABA">Cabaletta Bio</a> Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, has announced new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. These trials are evaluating the efficacy of rese-cel (resecabtagene autoleucel) in treating autoimmune diseases. The data, based on 18 evaluable patients, are being presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain, held from June 11-14, 2025. Key findings include clinically meaningful responses in myositis patients, remission in SLE patients without nephropathy, and improvement in scleroderma patients, with most patients off immunomodulators and steroids. Safety data indicate a low incidence of CRS and ICANS. Cabaletta Bio plans to engage with the FDA on registrational program designs for various indications to advance the development of rese-cel as a targeted curative cell therapy for autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466601-en) on June 11, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542303588"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542303588\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542303588?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542303588","market":"us","top_or_hot":-1,"title":"Cabaletta Bio Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, has announced new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. These trials are evaluating the efficacy of rese-cel (resecabtagene autoleucel) in treating autoimmune diseases. The data, based on 18 evaluable patients, are being presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain, held from June 11-14, 2025. Key findings include clinically meaningful responses in myositis patients, remission in SLE patients without nephropathy, and improvement in scleroderma patients, with most patients off immunomodulators and steroids. Safety data indicate a low incidence of CRS and ICANS. Cabaletta Bio plans to engage with the FDA on registrational program designs for various indications to advance the development of rese-cel as a targeted curative cell therapy for autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466601-en) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cabaletta Bio Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCabaletta Bio Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-11 18:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, has announced new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. These trials are evaluating the efficacy of rese-cel (resecabtagene autoleucel) in treating autoimmune diseases. The data, based on 18 evaluable patients, are being presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain, held from June 11-14, 2025. Key findings include clinically meaningful responses in myositis patients, remission in SLE patients without nephropathy, and improvement in scleroderma patients, with most patients off immunomodulators and steroids. Safety data indicate a low incidence of CRS and ICANS. Cabaletta Bio plans to engage with the FDA on registrational program designs for various indications to advance the development of rese-cel as a targeted curative cell therapy for autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466601-en) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL5VHBF2:1","article_id":"2542303588","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542303588","pubTimestamp":1749636029,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cabaletta Bio, Inc. , a clinical-stage biotechnology company, has announced new clinical and translational data from its ongoing RESET-Myositis, RESET-SLE, and RESET-SSc trials. These trials are evaluating the efficacy of rese-cel  in treating autoimmune diseases. The data, based on 18 evaluable patients, are being presented at the European Alliance of Associations for Rheumatology  2025 Congress in Barcelona, Spain, held from June 11-14, 2025. Key findings include clinically meaningful responses in myositis patients, remission in SLE patients without nephropathy, and improvement in scleroderma patients, with most patients off immunomodulators and steroids. Safety data indicate a low incidence of CRS and ICANS. Cabaletta Bio plans to engage with the FDA on registrational program designs for various indications to advance the development of rese-cel as a targeted curative cell therapy for autoimmune diseases.Disclaimer: This news brief was created by Public Technologies  using generativ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","CABA":"Cabaletta Bio","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Cabaletta Bio在EULAR 2025大会上公布了Rese-cel治疗肌炎、狼疮和硬皮病的有希望的临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CABA":0.9,"NDAQ":0.9},"content_text":"Cabaletta Bio Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress\n    \n\n        Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, has announced new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. These trials are evaluating the efficacy of rese-cel (resecabtagene autoleucel) in treating autoimmune diseases. The data, based on 18 evaluable patients, are being presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain, held from June 11-14, 2025. Key findings include clinically meaningful responses in myositis patients, remission in SLE patients without nephropathy, and improvement in scleroderma patients, with most patients off immunomodulators and steroids. Safety data indicate a low incidence of CRS and ICANS. Cabaletta Bio plans to engage with the FDA on registrational program designs for various indications to advance the development of rese-cel as a targeted curative cell therapy for autoimmune diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466601-en) on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}